Search results
Showing 1021 to 1035 of 1134 results for criteria
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.
who are heterozygous for the CFTR mutations listed under the eligibility criteria for ivacaftor as a monotherapy in table 4 . b....
This guideline covers interventions to maintain and improve the mental wellbeing and independence of people aged 65 or older and how to identify those most at risk of a decline.
Social, emotional and mental wellbeing in primary and secondary education (NG223)
This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
Discontinued Reference number: GID-TA11289
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.
Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.